Unknown

Dataset Information

0

Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.


ABSTRACT: Considering the strong association between dysregulated insulin-like growth factor (IGF) signaling and various human cancers, we have used an expedient combination of genetic analysis and pharmacological treatment to evaluate the potential of the type 1 IGF receptor (Igf1r) for targeted anticancer therapy in a mouse model of mammary tumorigenesis. In this particular strain of genetically modified animals, histopathologically heterogeneous invasive carcinomas exhibiting up-regulation of the Igf1r gene developed extremely rapidly by mammary gland-specific overexpression of constitutively active oncogenic Kras* (mutant Kras(G12D)). Immunophenotyping data and expression profiling analyses showed that, except for a minor luminal component, these mouse tumors resembled basal-like human breast cancers. This is a group of aggressive tumors of poor prognosis for which there is no targeted therapy currently available, and it includes a subtype correlating with KRAS locus amplification. Conditional ablation of Igf1r in the mouse mammary epithelium increased the latency of Kras*-induced tumors very significantly (approximately 11-fold in comparison with the intact model), whereas treatment of tumor-bearing animals by administration of picropodophyllin (PPP), a specific Igf1r inhibitor, resulted in a dramatic decrease in tumor mass of the main forms of basal-like carcinomas. PPP also was effective against xenografts of the human basal-like cancer cell line MDA-MB-231, which carries a KRAS(G13D) mutation.

SUBMITTER: Klinakis A 

PROVIDER: S-EPMC2650161 | biostudies-literature | 2009 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.

Klinakis Apostolos A   Szabolcs Matthias M   Chen Guoying G   Xuan Shouhong S   Hibshoosh Hanina H   Efstratiadis Argiris A  

Proceedings of the National Academy of Sciences of the United States of America 20090127 7


Considering the strong association between dysregulated insulin-like growth factor (IGF) signaling and various human cancers, we have used an expedient combination of genetic analysis and pharmacological treatment to evaluate the potential of the type 1 IGF receptor (Igf1r) for targeted anticancer therapy in a mouse model of mammary tumorigenesis. In this particular strain of genetically modified animals, histopathologically heterogeneous invasive carcinomas exhibiting up-regulation of the Igf1r  ...[more]

Similar Datasets

| S-EPMC3092264 | biostudies-literature
| S-EPMC6627083 | biostudies-other
| S-EPMC3515719 | biostudies-literature
| S-EPMC6510844 | biostudies-literature
| S-EPMC9769962 | biostudies-literature
| S-EPMC5187506 | biostudies-literature
| S-EPMC9735829 | biostudies-literature
| S-EPMC5288174 | biostudies-literature
2020-04-13 | GSE110659 | GEO
| S-EPMC5979567 | biostudies-literature